Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

HAMPS BIO LTD.

NSE : NABSE : 544312ISIN CODE : INE0QBD01018Industry : TradingHouse : Private

BSE101.7450.74 (+99.49 %)

PREV CLOSE ( ) 51.00

OPEN PRICE ( ) 96.90

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 484000

TODAY'S LOW / HIGH ( )96.90 101.74

52 WK LOW / HIGH ( ) 96.9101.74

NSE

This Company is not listed in NSE

Select year

Particulars

Mar 2024

Mar 2023

Mar 2022

Operational & Financial Ratios

Earnings Per Share (Rs)

2.55

2.39

0.81

CEPS(Rs)

2.88

2.91

1.86

DPS(Rs)

0.00

Book NAV/Share(Rs)

17.22

9.09

6.70

Tax Rate(%)

22.97

-0.53

-15.94

Margin Ratios

Core EBITDA Margin(%)

18.18

15.53

11.52

EBIT Margin(%)

12.35

9.58

5.51

Pre Tax Margin(%)

10.04

6.40

1.96

PAT Margin (%)

7.73

6.44

2.28

Cash Profit Margin (%)

13.97

12.51

8.36

Performance Ratios

ROA(%)

11.10

9.53

3.37

ROE(%)

21.14

30.31

12.08

ROCE(%)

21.27

17.38

9.66

Asset Turnover(x)

1.44

1.48

Sales/Fixed Asset(x)

1.43

1.38

1.44

Working Capital/Sales(x)

6.27

-6.63

-11.34

Efficiency Ratios

Fixed Capital/Sales(x)

0.70

0.72

0.70

Receivable days

49.29

47.45

47.20

Inventory Days

44.96

30.62

38.87

Payable days

84.03

90.36

63.71

Valuation Parameters

PER(x)

0.00

PCE(x)

0.00

Price/Book(x)

0.00

Yield(%)

EV/Net Sales(x)

0.46

0.57

0.65

EV/Core EBITDA(x)

2.45

3.65

5.64

EV/EBIT(x)

3.68

5.97

11.86

EV/CE(x)

0.67

1.03

1.15

M Cap / Sales

0.00

Growth Ratio

Net Sales Growth(%)

16.08

4.45

0.00

Core EBITDA Growth(%)

37.82

40.91

0.00

EBIT Growth(%)

49.64

81.52

0.00

PAT Growth(%)

39.47

195.47

0.00

EPS Growth(%)

6.74

195.47

0.00

Financial Stability Ratios

Total Debt/Equity(x)

0.31

1.27

2.03

Current Ratio(x)

1.73

0.59

0.74

Quick Ratio(x)

0.86

0.42

Interest Cover(x)

5.34

3.01

1.55

Total Debt/Mcap(x)